TOVX · Theriva Biologics, Inc.

NYSEHealthcareBiotechnology

Theriva Biologics Inc Is A Clinical-Stage Pharmaceutical Company Developing A Novel Oncolytic Adenovirus (Ov) Platform To Address Devastating Cancers With High Unmet Needs. It Is A Clinical-Stage Program Vcn-01, Designed To Break Down The Tumor Stroma, And Its Preclinical-Stage Program Vcn-11 Leverages Its Proprietary Albumin Shield Technology To Protect Systemically Administered Oncolytic Viruses From The Host Immune System. Product Candidates Includes Syn-004 (Ribaxamase) And Syn-020.

HealthcareNYSEUSMid Float

$0.85

+153.7% latest move

Price & move as of the most recent catalyst (Oct 23) — not a live quote.

FLOAT

45.4M

FREE FLOAT %

99%

SHARES O/S

45.9M

MARKET CAP

$10.1M

EXCHANGE

NYSE

COUNTRY

TOVX Catalyst History

Legal and ComplianceOct 23, 2025 · 7:59pm ET

TOVXTheriva Biologics, Inc.

Be early on the next TOVX spark.

Day Trader Sniper alerts you the instant a setup like this triggers.

How it works Download Free →

TOVX · Theriva Biologics, Inc.

TOVX Catalyst History

Theriva Biologics Addresses Unusual Trading Activity

Theriva Biologics Addresses Unusual Trading Activity

Theriva Biologics Announces Pricing Of $7.5M Public Offering And Reports VIRAGE Phase 2b Trial Findings

Theriva Biologics Announces Pricing Of $7.5M Public Offering And Reports VIRAGE Phase 2b Trial Findings